Influence of Location and Mitotic Index on Prognosis in Patients with Gastrointestinal Stromal Tumors

• Authors: Sławomir Mrowiec , Beata Jabłońska , Marcin Leidgens , Jacek Pająk , Paweł Lampe
• Languages of publication: EN

Abstracts

EN

Gastrointestinal stroma tumors (GIST) arise from the pacemaker, the interstitial Wells of Cajal. These tumors constitute 1 to 3% of gastrointestinal neoplasms, and may occur in each portion of the gastrointestinal tract. The most useful prognostic factors are tumor size, mitotic index, cell structure and location within the gastrointestinal tract.The aim of the study was to assess the chosen prognostic factors (location in the gastrointestinal tract and mitotic index) in patients with GIST.Material and methods. Between 1989 and 2002, 74 patients (37 men and 37 women) with an average age of 54.9 years (range from 13 to 89 years) were operated for GIST in the Department of Gastrointestinal Surgery. Two- and five-year survival rates during observation were analyzed, as well as the location within the gastrointestinal tract and mitotic index. Based on the intraoperative and postoperative investigations, the tumor size, presence of metastases and histological type of predominant cells were estimated in each patent. Results were subjected to statistics, where p≤0.05 was considered to be significant.Results. Of the 74 patients included in the study, 3 patients (4%) had a primary tumor located in the lower oesophagus, 42 patients (56.8%) in the stomach, 4 patients (5.4%) in the duodenum, and 13 patients (17.6%) had tumors originated from the small intestine. In an additional 12 patients (16.2%), the tumor originated from the large intestine. The most frequent (51%) mitotic index was 2, and 9/50 hpf was considered an intermediate malignant potential risk. Two-year survival was common in patients with GIST located in the oesophagus, stomach, and duodenum, totalling 34 (79%) patients. A lower than two-year survival rate was noted in patients with GIST arising from the small intestine: 7 (63.6%) patients had tumors arising from the colon and 4 (36.3%) patients had rectal tumors. Five-year survival was also the most frequent in patients with GIST located in the upper part of gastrointestinal tract (37.2%), in the median part of gastrointestinal tract (36.3%), and in the lower part of the gastrointestinal tract (27.7%). Correlation between location, mitotic index and survival of patients was assessed. The correlation studies showed a statistically significant influence of tumor location in the gastrointestinal tract (p=0.0264) and mitotic index (p=0.0003) with the survival of patients operated for GIST. Thus, the lower location and higher mitotic index of GIST are associated with shorter survival of patients.Conclusions. The mitotic index and location in the gastrointestinal tract are essential prognostic factors in analyzed patients with GIST. In the analyzed group, the lower locations and higher mitotic indices of GIST were associated with shorter survival of patients.

Keywords

EN

GIST; prognostic factors; mitotic index

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2008
• Volume: 80
• Issue: 6
• Pages: 321-330

Dates

published

1 - 6 - 2008

online

19 - 6 - 2008

Contributors

author

Sławomir Mrowiec

• Department of Gastrointestinal Surgery, Silesian Medical University, Katowice

author

Beata Jabłońska

• Department of Gastrointestinal Surgery, Silesian Medical University, Katowice

author

Marcin Leidgens

• Department of General Surgery, T. Chałubiński Memorial Hospital, Zakopane

author

Jacek Pająk

• Department of Pathology, Silesian Medical University, Katowice

author

Paweł Lampe

• Department of Gastrointestinal Surgery, Silesian Medical University, Katowice

References

• Noguchi T, Sato T, Takeno S et al: Biological analysis of gastrointestinal stromal tumors. Oncol Rep 2002; 9(6): 1277-82.[PubMed]
• Pidhorecky I, Cheney RT, Kraybill WG et al: Gastrointestinal stromal tumors: current diagnosis, biologic behavior and management. Ann Surg Oncol 2000; 7: 705-12.[Crossref][PubMed]
• Davis GB, Blanchard DK, Hatch GF et al: Tumors of the stomach. World J Surg 2000; 24(4): 412-20.[Crossref][PubMed]
• Miettinen M, Lasota J Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
• Fletcher CD, Berman JJ, Corless C et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum-Pathol 2002; 33(5): 459-65.[PubMed][Crossref]
• Rutkowski P, Nowecki ZI, Nowak-Dement A Nowotwory zrębu przewodu pokarmowego - obraz kliniczno-morfologiczny. Pol Przegl Chir 2003; 75(4): 374-84.
• Jabłońska B, Ciupińska-Kajor M, Lampe P Łagodne guzy przełyku - analiza kliniczno-morfologiczna. Pol Przegl Chir 2004; 76(4): 383-98.
• Nakagawa M, Akasaka Y, Kanai T et al: Extragastrointestinal stromal tumor of the greater omentum: case report and review of the literature. Hepatogastroenterology 2003; 50(51): 691-95.[PubMed]
• Reith JD, Goldblum JR, Lyles RH et al: Extragastrointestinal (Soft Tissue) Stromal Tumors: an analysis of 48 cases with emphasis on histologic predictors and outcome. Mod Pathol 2000; 13(5): 577-85.[Crossref][PubMed]
• Hasegawa T, Matsuno Y, Shimoda T et al: Gastrointestinal stromal tumor: consistent CD117 immunostaging for diagnosis and prognostic classification based on tumor size and MIB-1 grade. Hum-Pathol 2002; 33(6): 669-76.
• Pierie JP, Choudry U, Muzikansky A et al: The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch-Surg 2001; 136(4): 383-89.
• DeMatteo RP, Lewis JJ, Leung D et al: Two hundred gastrointestinal stromal tumors: recurrence and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
• Mudan SS, Conlon KC, Woodruff JM et al: Salvage surgery for patients with recurrent gastrointestinal sarcoma prognostic factors to guide patient selection. Cancer 2000; 88(1): 66-74.[Crossref][PubMed]
• Hirota S, Isozaki K, Moriyama Y et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279(5350): 577-80.
• Kindblom LG, Remotti HE, Aldenborg F et al: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152(5): 1259-69.
• Nigri GR, Dente M, Valabrega S et al: Gastrointestinal stroma tumor of the anal canal: an unusual presentation. Word J Surg Oncol 2007; 5: 20-24.[Crossref]
• Joensuu H Gastrointestinal stromal tumor (GIST). Ann Oncol 2007; 17: 280-86.
• Emory TS, Sobin LH, Lukes L et al: Prognosis of gastrointestinal smooth-muscle/stromal/tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23(1): 82-87.[Crossref][PubMed]
• Kovac D, Petrovecki M, Jasic M et al: Prognostic factors of gastrointestinal stromal tumors. Anticancer-Res. 2002; 22(3): 1913-17.[PubMed]
• Ueyama T, Guo KJ, Hashimoto H et al: A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992; 69(4): 947-55.[PubMed][Crossref]
• Bdioui H, Jouni M, Bouzaiene H et al: Gastrointestinal stromal tumours: clinical and therapeutic features. A report of 25 cases. Tunis Med 2006; 84(10): 599-602.[PubMed]
• Ting-Jung Wu, Li-Yu Lee, Hun-Nan Yeh. et al: Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imanitib mesylate. Gastroenterol 2006; 6: 29.
• Hinz S, Pauser U, Egberts JH et al: Audit of a series of 40 gastrointestinal stromal tumour cases. Eur J Surg Oncol 2006; 32(10): 1125-29.[Crossref][PubMed]
• Chiappa A, Zbar AP, Biffi R et al: Prognostic factors and outcome of resected patients for gastrointestinal stromal tumors. Hepatogastroenterol 2007; 54(75): 693-96.
• Dematteo RP, Gold JS, Saran L et al: Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2007; Dec 12 (Epub ahead of print).
• Bertin M, Angriman I, Scarpa M et al: Prognosis of gastrointestinal stromal tumors. Hepatogastroenterol 2007; 54(73): 124-28.
• Perez EA, Gutierrez JC, Jin X et al: Surgical Outcomes of gastrointestinal sarcoma including gastrointestinal stroma tumors: a population-based examination. J Gastrointest Surg 2007; 11(1): 114-15.[Crossref]
• Gold JS, DeMatteo RP Combined Surgical and Molecular Therapy. The Gastrointestinal Stromal Tumor Model. Ann Surg 2006; 244(2): 176-84.
• Rutkowski P, Nowecki ZI, Michej W et al: Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 2007; 14(7): 2018-27.[PubMed][Crossref]
• Lasota J, vel Dobosz AJ, Wasag B et al: Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 2007; 87(10): 1029-41.[Crossref]
• Hassan I, You YN, Dozois EJ et al: Clinical, pathologic, and immunohistochemical characteristicks of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Dis Colon Rectum 2006; 49(5): 609-15.[PubMed][Crossref]
• Rutkowski P, Debiec-Rychter M, Nowecki M et al: Different factors are responsible for predicting relapses after primary tumors resection and for imanitib treatment outcomes in gastrointestinal stromal tumors. Med Sci Monit 2007; 13(11): 515-22.
• Druker BJ, Talpaz M, Resta DJ et al: Efficacy and safety of a specific inhibitor of BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031-37.
• Heinrich MC, Corless CL, Duensing A et al: PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors. Science 2003; 299(5607): 708-10.
• Tuveson DA, Willis NA, Jacks T et al: STI 571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001 Aug 16; 20(36): 5054-58.
• Oosterom van AT, Judson I, Verweij J et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors; a phase I study. Lancet 2001 27; 358(9291): 1421-23.
• Patel SR Early results randomized phase III of imatinib mesylate for gastrointestinal stromal tumors. Curr-Oncol-Rep 2003; 5(4): 273.[PubMed]
• Chou FF, Eng HL, Sheen-Chen SM Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. Surgery 1996; 119(2): 171-77.[PubMed][Crossref]
• Dougherty MJ, Compton C, Talbert M et al: Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. Ann-Surg 1991; 214(5): 569-74.
• Franquemont DW Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103(1): 41-47.[PubMed]
• Lewis JJ, Leung D, Woodruff JM et al: Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann-Surg 1998; 228(3): 355-65.
• Catena F, Pasqualini E, Campione O Gastrointestinal stromal tumors: experience of an Emergency Surgery Department. Dig Surg 2000; 17(5): 503-07.[Crossref][PubMed]
• Cunningham RE, Federspiel BH, McCarthy WF et al: Predicting prognosis of gastrointestinal stromal smooth muscle tumors. Role of clinical histological evaluation, flow cytometry and image cytometry. Am J Surg Pathol 1993; 17(6): 588-94.[Crossref]
• Rudolph P, Gloeckner K, Parwaresch R et al: Immunophenotype, proliferation, DNA-ploidy and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum-Pathol 1998; 29(8): 791-800.[PubMed][Crossref]
• Cooper PN, Quirke P, Hardy GJ et al: A flow cytometric, clinical and histological study of stromal neoplasms of the gastrointestinal tract. Am J Surg Pathol 1992; 16(2): 163-70.[Crossref][PubMed]
• Pidhorecky I, Cheney RT, Kraybill WG et al: Gastrointestinal stromal tumors: current diagnosis, biologic behavior and management. Ann Surg Oncol 2000; 7: 705-12.[Crossref][PubMed]
• Winfield RD, Hochwald SN, Vogel SB et al: Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg 2006; 72(8): 719-22.[PubMed]
• Agaimy A, Wunsch PH, Sobin LH et al: Occurrence of other malignancies in patients with gastyrointestinal stromal tumors. Semin Diagn Pathol 2006; 23(2): 120-29.[Crossref]
• Katsoulis IE, Bossi M, Richman PI et al: Collision of adenocarcinoma and gastrointestinal stromal tumour (GIST) in the stomach: report of a case. Int Sem Surg Oncol 2007; 4: 2.[Crossref]
• Wronski M, Ziarkiewicz-Wroblewska B, Gornicka B et al: Synchronous occurence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. Word J Gastroenterol 2006; 12(33): 5360-62.
• Liszka Ł, Zielińska-Pająk E, Pająk J et al: Coexistence of gastrointestinal stroma tumors with other neoplasms. J Gastroenterol 2007; 42(8): 641-49.[Crossref]
• DeMatteo RP, Heinrich MC, El-Rifafi WM et al: Clinical management of gastrointestinal stromal tumors: before and after STI 571. Hum Pathol 2002; 33: 466-77.[Crossref][PubMed]
• Lev D, Kariv Y, Issakov J et al: Gastrointestinal stromal sarcomas. Br J Surg 1999; 86(4): 545-49.[Crossref][PubMed]
• Ryan DP, Puchalski T, Supko JG et al: A phase II and pharmacocinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002; 7(6): 531-38.
• Lopez M, Comandone A, Adamo V et al: Clinical Guidelines for the management of gastrointestinal stromal tumors. Clin Ter 2006; 157(3): 283-99.
• Andtbacka RH, Ng CS, Scaife CL et al: Surgical resection of gastrointestinal stromal tumors after treatment with imanitib. Ann Surg Oncol 2007; 14(1): 14-24.

Identifiers

DOI

10.2478/v10035-008-0044-z